[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100473719":3},{"organization":4,"outcomesModule":7,"designInfo":64,"detailedDescription":72,"studyPopulation":69,"armGroups":73,"interventions":87,"overallOfficials":101,"centralContacts":105,"locations":114,"responsibleParty":476,"collaborators":479,"id":483,"slug":484,"hasResults":485,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":491,"sex":492,"minAge":493,"maxAge":69,"enrollmentInfo":494,"targetDuration":69,"studyType":497,"phases":498,"briefSummary":500,"conditions":501,"keywords":503,"overallStatus":117,"whyStopped":69,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":517},{"fullName":5,"class":6},"The Hospital of Vestfold","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":45},[9,13],{"measure":10,"description":11,"timeFrame":12},"Overall survival","overall survival","10 years following end of recruitment",{"measure":14,"description":15,"timeFrame":16},"Burden of disease","European Organisation for Research and Treatment of Cancer questionnaire for assessment of health-related quality of life elderly patients with cancer (EORTC ELD 14), burden of disease scale (2 questions, score 0-100, high scores indicate high burden of disease)","0-10 years",[18,21,24,27,30,33,36,39,42],{"measure":19,"description":20,"timeFrame":16},"Role functioning","European Organisation for Research and Treatment of Cancer questionnaire for quality of life of cancer patients (EORTC-QLQ-C30), RF2 scale (2 questions, score 0-100, high scores indicate a high \u002F healthy level of functioning)",{"measure":22,"description":23,"timeFrame":16},"Urinary irritative\u002F obstructive symptoms","Expanded Prostate Cancer Index Composite Short Form questionnaire (EPIC-26),urinary scales (score 0-100, higher scores indicating better outcomes)",{"measure":25,"description":26,"timeFrame":16},"bowel symptoms","Expanded Prostate Cancer Index Composite Short Form questionnaire (EPIC-26), bowel scales (score 0-100, higher scores indicating better outcomes)",{"measure":28,"description":29,"timeFrame":16},"Prostate cancer morbidity","hospitalizations, interventions, complications due to local progression\u002F systemic progression)",{"measure":31,"description":32,"timeFrame":16},"Prostate-cancer-specific survival","Prostate cancer deaths in intervention and control group",{"measure":34,"description":35,"timeFrame":16},"Metastasis-free survival","time to metastasis detected radiographically due to symptoms or biochemical progression",{"measure":37,"description":38,"timeFrame":16},"Symptom-\u002F intervention-free survival","time to symptoms\u002F need for interventions due to prostate cancer progression",{"measure":40,"description":41,"timeFrame":16},"Quality of life-adjusted years","Euro QoL group questionaire (EQ-5D-5L) (1 =full health; 0= dead)",{"measure":43,"description":44,"timeFrame":16},"need for secondary and tertiary therapy","use of second- and third-line therapies",[46,49,52,55,58,61],{"measure":47,"description":48,"timeFrame":16},"Institutionalized care","at each follow-up visit the living status of the patients will be assessed. If patients have become dependent on permanent nursing home\u002F assisted care this will be registered.",{"measure":50,"description":51,"timeFrame":16},"Health-related quality of life in cancer patients","European Organisation for Research and Treatment of Cancer questionnaire for quality of life of cancer patients (EORTC-QLQ-C30), scales not primary\u002F secondary outcome measures (All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high \u002F healthy level of functioning, a high score for the global health status \u002F QoL represents a high QoL, but a high score for a symptom scale \u002F item represents a high level of symptomatology \u002F problems)",{"measure":53,"description":54,"timeFrame":16},"Health-related quality of life in older cancer patients","European Organisation for Research and Treatment of Cancer questionnaire for quality of life of cancer patients (EORTC-QLQ-C30), scales not primary outcome (All of the scales and single-item measures range in score from 0 to 100. High scores indicate poor mobility, good family support, much worry about the future, good maintenance of autonomy and purpose)",{"measure":56,"description":57,"timeFrame":16},"Quality of Life issues in patients with prostate cancer","Expanded Prostate Cancer Index Composite Short Form questionnaire (EPIC-26), scales not secondary outcomes (score 0-100, higher scores indicating better outcomes)",{"measure":59,"description":60,"timeFrame":16},"Instrumental activities of daily living (iADL)","Lawton and Brody questionnaire (8 questions, minimum score 0, maximum score 5, higher scores indicating need for assistance)",{"measure":62,"description":63,"timeFrame":16},"Personal activities of daily living (pADL)","Lawton and Brody questionnaire (6 questions, minimum score 0, maximum score 5, higher scores indicating need for assistance)",{"allocation":65,"interventionModel":66,"interventionModelDescription":67,"primaryPurpose":68,"observationalModel":69,"timePerspective":69,"maskingInfo":70},"RANDOMIZED","PARALLEL","randomized, parallel, open-label","TREATMENT",null,{"masking":71,"maskingDescription":69,"whoMasked":69},"NONE","There is a lack of both level 1 evidence and consensus regarding the optimal treatment strategy for older men (\\>=75 years) with non-metastatic, high-risk prostate cancer. Currently, in Scandinavia, the majority of older patients are treated conservatively, i.e. with hormone therapy or watchful waiting while some centers recommend immediate curative therapy regardless of patient age. Older patients thus risk both undertreatment and overtreatment of their cancer. This randomized clinical trial investigates if immediate curative therapy of high-risk, non-metastatic prostate cancer prolongs life (as it does in younger patients) and improves health-related quality of life. Furthermore, this trial investigates if the early side effects of immediate curative therapy are compensated by better long-term tumor control, better quality of life, functional status and improved survival.",[74,80],{"label":75,"type":76,"description":77,"interventionNames":78},"immediate curative therapy","EXPERIMENTAL","Patients randomized to the intervention arm will receive immediate curative therapy in the form of either radiotherapy to the prostate in combination with hormone therapy (ADT or monotherapy) or surgery (radical prostatectomy). Standard treatment in this arm is radiotherapy + hormone therapy. Surgery is reserved for patients with strong preferences against radiotherapy.",[79],"Radiation: Radiotherapy or surgery",{"label":81,"type":82,"description":83,"interventionNames":84},"initial observation\u002F hormone therapy","ACTIVE_COMPARATOR","Patients in this arm will either be observed (with localized high-risk prostate cancer) or receive hormone therapy (locally advanced prostate cancer; ADT or monotherapy). Further local or systemic therapy is given at doctor's discretion triggered by local or\u002F and systemic progression.",[85,86],"Other: initial observation","Drug: Hormone therapy",[88,93,96],{"type":89,"name":90,"description":91,"armGroupLabels":92,"otherNames":69},"RADIATION","Radiotherapy or surgery","see arm\u002F group description",[75],{"type":6,"name":94,"description":91,"armGroupLabels":95,"otherNames":69},"initial observation",[81],{"type":97,"name":98,"description":99,"armGroupLabels":100,"otherNames":69},"DRUG","Hormone therapy","androgen depression therapy (ADT) by either LHRH agonist or antagonist or androgen monotherapy",[81],[102],{"name":103,"affiliation":5,"role":104},"Sven Loffeler, MD, PhD","PRINCIPAL_INVESTIGATOR",[106,110],{"name":103,"role":107,"phone":108,"phoneExt":69,"email":109},"CONTACT","+4792235628","sven.loffeler@siv.no",{"name":111,"role":107,"phone":112,"phoneExt":69,"email":113},"Erik S Haug, MD, PhD","+4793030298","erik.haug@siv.no",[115,132,145,158,173,186,200,216,230,245,260,275,291,305,318,327,344,357,372,386,399,412,425,439,449,463],{"facility":116,"status":117,"city":118,"state":69,"zip":69,"country":119,"countryCode":120,"cosmosGeoPoint":121,"geoPoint":126,"contacts":127},"Rigshospital","RECRUITING","Copenhagen","Denmark","DK",{"type":122,"coordinates":123},"Point",[124,125],12.56553,55.67594,{"lat":125,"lon":124},[128],{"name":129,"role":107,"phone":130,"phoneExt":69,"email":131},"Klaus Brasso, Prof, PhD","+45 35 45 35 45","klaus.brasso@regionh.dk",{"facility":133,"status":117,"city":134,"state":69,"zip":69,"country":119,"countryCode":120,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Esbjerg and Grindsted Hospital","Esbjerg",{"type":122,"coordinates":136},[137,138],8.45187,55.47028,{"lat":138,"lon":137},[141],{"name":142,"role":107,"phone":143,"phoneExt":69,"email":144},"Mads Hvid Aaberg Poulsen, Associate Professor","+45 2176 5418","mads.poulsen@rsyd.dk",{"facility":146,"status":117,"city":147,"state":69,"zip":69,"country":119,"countryCode":120,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"Odense University Hospital","Odense",{"type":122,"coordinates":149},[150,151],10.38831,55.39594,{"lat":151,"lon":150},[154],{"name":155,"role":107,"phone":156,"phoneExt":69,"email":157},"Grzegorz Lukasz H Fojecki, MD, PhD","+45 63 20 20 00","grzegorz.lukasz.fojecki@rsyd.dk",{"facility":159,"status":117,"city":160,"state":69,"zip":161,"country":162,"countryCode":163,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"Helsinki University Hospital","Helsinki","00029","Finland","FI",{"type":122,"coordinates":165},[166,167],24.93545,60.16952,{"lat":167,"lon":166},[170],{"name":171,"role":107,"phone":172,"phoneExt":69,"email":69},"Antti Rannikko, Professor, MD, PhD","+358 9 4711",{"facility":174,"status":117,"city":175,"state":69,"zip":69,"country":162,"countryCode":163,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"Tampere University Hospital","Tampere",{"type":122,"coordinates":177},[178,179],23.78712,61.49911,{"lat":179,"lon":178},[182],{"name":183,"role":107,"phone":184,"phoneExt":69,"email":185},"Teemu Murtola, Prof, PhD","+358 3 311 611","teemu.murtola@tuni.fi",{"facility":187,"status":117,"city":188,"state":69,"zip":189,"country":162,"countryCode":163,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"Turku University Hospital","Turku","20520",{"type":122,"coordinates":191},[192,193],22.26869,60.45148,{"lat":193,"lon":192},[196],{"name":197,"role":107,"phone":198,"phoneExt":69,"email":199},"Otto Ettala, MD, PhD","+358 2 313 0000","Otto.Ettala@tyks.fi",{"facility":201,"status":117,"city":202,"state":203,"zip":69,"country":204,"countryCode":205,"cosmosGeoPoint":206,"geoPoint":210,"contacts":211},"Sunmøre Hospital Trust","Ålesund","Møre og Romsdal","Norway","NO",{"type":122,"coordinates":207},[208,209],6.15492,62.47225,{"lat":209,"lon":208},[212],{"name":213,"role":107,"phone":214,"phoneExt":69,"email":215},"Bjørg Aksnessæther","+47 70105000","bjorg.y.aksnessether@helse-mr.no",{"facility":217,"status":117,"city":218,"state":219,"zip":69,"country":204,"countryCode":205,"cosmosGeoPoint":220,"geoPoint":224,"contacts":225},"Stavanger University Hospital","Stavanger","Rogaland",{"type":122,"coordinates":221},[222,223],5.73332,58.97005,{"lat":223,"lon":222},[226],{"name":227,"role":107,"phone":228,"phoneExt":69,"email":229},"Maria Nyre Vigmostad, MD","+47 51518000","marianyr@gmail.com",{"facility":231,"status":117,"city":232,"state":233,"zip":234,"country":204,"countryCode":205,"cosmosGeoPoint":235,"geoPoint":239,"contacts":240},"Sørlandet Hospital Trust","Kristiansand","Sørlandet","4604",{"type":122,"coordinates":236},[237,238],7.9956,58.14671,{"lat":238,"lon":237},[241],{"name":242,"role":107,"phone":243,"phoneExt":69,"email":244},"Christoph Müller, MD, PhD","+47 90610600","christoph.muller@sshf.no",{"facility":246,"status":117,"city":247,"state":248,"zip":249,"country":204,"countryCode":205,"cosmosGeoPoint":250,"geoPoint":254,"contacts":255},"Telemark Hospital Trust","Skien","Telemark","3710",{"type":122,"coordinates":251},[252,253],9.60897,59.20962,{"lat":253,"lon":252},[256],{"name":257,"role":107,"phone":258,"phoneExt":69,"email":259},"Rasmus Nilsson, MD","+47 35003500","Rasmus.Nilsson@sthf.no",{"facility":261,"status":117,"city":262,"state":263,"zip":264,"country":204,"countryCode":205,"cosmosGeoPoint":265,"geoPoint":269,"contacts":270},"St. Olavs Hospital","Trondheim","Trøndelag","7006",{"type":122,"coordinates":266},[267,268],10.39506,63.43049,{"lat":268,"lon":267},[271],{"name":272,"role":107,"phone":273,"phoneExt":69,"email":274},"Torgrim M Tandstad, MD, PhD, Professor","+47 72573000","Torgrim.Tandstad@stolav.no",{"facility":276,"status":117,"city":277,"state":278,"zip":279,"country":204,"countryCode":205,"cosmosGeoPoint":280,"geoPoint":284,"contacts":285},"Vestfold Hospital Trust (Hospital of Vestfold)","Tønsberg","Vestfold","3103",{"type":122,"coordinates":281},[282,283],10.40762,59.26754,{"lat":283,"lon":282},[286,289],{"name":287,"role":107,"phone":288,"phoneExt":288,"email":109},"Sven Löffeler","+4733342000",{"name":290,"role":107,"phone":288,"phoneExt":288,"email":113},"Erik S Haug",{"facility":292,"status":117,"city":293,"state":69,"zip":294,"country":204,"countryCode":205,"cosmosGeoPoint":295,"geoPoint":299,"contacts":300},"Vestre Viken Hospital Trust","Drammen","3004",{"type":122,"coordinates":296},[297,298],10.20449,59.74389,{"lat":298,"lon":297},[301],{"name":302,"role":107,"phone":303,"phoneExt":69,"email":304},"Jon G Tyrdal, MD","+47 32803000","jongt@hotmail.com",{"facility":306,"status":117,"city":307,"state":69,"zip":69,"country":204,"countryCode":205,"cosmosGeoPoint":308,"geoPoint":312,"contacts":313},"Innlandet Hospital Trust","Hamar",{"type":122,"coordinates":309},[310,311],11.06798,60.7945,{"lat":311,"lon":310},[314],{"name":315,"role":107,"phone":316,"phoneExt":69,"email":317},"Ola Christiansen, MD","+47 915 06 200","ola.christiansen@sykehuset-innlandet.no",{"facility":319,"status":117,"city":320,"state":69,"zip":321,"country":204,"countryCode":205,"cosmosGeoPoint":69,"geoPoint":69,"contacts":322},"Akerhus University Hospital","Lørenskog","1478",[323],{"name":324,"role":107,"phone":325,"phoneExt":69,"email":326},"Kirsti Aas, MD, PhD","+47 55 97 50 00","kirstiaas@hotmail.com",{"facility":328,"status":117,"city":329,"state":69,"zip":69,"country":204,"countryCode":205,"cosmosGeoPoint":330,"geoPoint":334,"contacts":335},"Oslo University Hospital","Oslo",{"type":122,"coordinates":331},[332,333],10.74609,59.91273,{"lat":333,"lon":332},[336,340],{"name":337,"role":107,"phone":338,"phoneExt":69,"email":339},"Kristian Thon, MD, PhD","+47 98227869","uxktho@ous-hf.no",{"name":341,"role":107,"phone":342,"phoneExt":69,"email":343},"Anne Marie Holck Storås, MD, PhD","+47 93208884","ANNHOL@ous-hf.no",{"facility":345,"status":117,"city":346,"state":69,"zip":69,"country":204,"countryCode":205,"cosmosGeoPoint":347,"geoPoint":351,"contacts":352},"University Hospital of Northern Norway","Tromsø",{"type":122,"coordinates":348},[349,350],18.95508,69.6489,{"lat":350,"lon":349},[353],{"name":354,"role":107,"phone":355,"phoneExt":69,"email":356},"Hege S Haugnes, Prof, PhD","+47 776 26000","hege.sagstuen.haugnes@unn.no",{"facility":358,"status":117,"city":359,"state":69,"zip":69,"country":360,"countryCode":361,"cosmosGeoPoint":362,"geoPoint":366,"contacts":367},"Falu Lasarett","Falun","Sweden","SE",{"type":122,"coordinates":363},[364,365],15.62597,60.60357,{"lat":365,"lon":364},[368],{"name":369,"role":107,"phone":370,"phoneExt":69,"email":371},"Nils Edström, MD","+460702742286","nils.edstrom@regiondalarna.se",{"facility":373,"status":117,"city":374,"state":69,"zip":375,"country":360,"countryCode":361,"cosmosGeoPoint":376,"geoPoint":380,"contacts":381},"Sahlgrenska University Hospital","Gothenburg","413 45",{"type":122,"coordinates":377},[378,379],11.96679,57.70716,{"lat":379,"lon":378},[382],{"name":383,"role":107,"phone":384,"phoneExt":69,"email":385},"Katarina Koss Modig, MD, PhD, FEBU","+46730123-0640","katarina.koss.modig@vgregion.se",{"facility":387,"status":117,"city":388,"state":69,"zip":69,"country":360,"countryCode":361,"cosmosGeoPoint":389,"geoPoint":393,"contacts":394},"Helsingborg\u002FÄngelholm hospital","Helsingborg",{"type":122,"coordinates":390},[391,392],12.69437,56.04673,{"lat":392,"lon":391},[395],{"name":396,"role":107,"phone":397,"phoneExt":69,"email":398},"Christian Torbrand, MD, PhD, Assosiate Professor","+46 76 8918588","christian.torbrand@skane.se",{"facility":400,"status":117,"city":401,"state":69,"zip":69,"country":360,"countryCode":361,"cosmosGeoPoint":402,"geoPoint":406,"contacts":407},"Örebro University Hospital","Örebro",{"type":122,"coordinates":403},[404,405],15.2066,59.27412,{"lat":405,"lon":404},[408],{"name":409,"role":107,"phone":410,"phoneExt":69,"email":411},"Henrik Ugge, MD","+46733391196","henrik.ugge@regionorebrolan.se",{"facility":413,"status":117,"city":414,"state":69,"zip":69,"country":360,"countryCode":361,"cosmosGeoPoint":415,"geoPoint":419,"contacts":420},"Östersunds Hospital","Östersund",{"type":122,"coordinates":416},[417,418],14.63566,63.1792,{"lat":418,"lon":417},[421],{"name":422,"role":107,"phone":423,"phoneExt":69,"email":424},"Andreas Lundgren, MD","+460735-33 68 55","andreas.m.lundgren@gmail.com",{"facility":426,"status":117,"city":427,"state":69,"zip":428,"country":360,"countryCode":361,"cosmosGeoPoint":429,"geoPoint":433,"contacts":434},"Capio Saint Göran's Hospital","Stockholm","11219",{"type":122,"coordinates":430},[431,432],18.06871,59.32938,{"lat":432,"lon":431},[435],{"name":436,"role":107,"phone":437,"phoneExt":69,"email":438},"Karin Holmsten, MD, PhD","+46 8 587 010 00","karin.holmsten@capiostgoran.se",{"facility":440,"status":117,"city":427,"state":69,"zip":441,"country":360,"countryCode":361,"cosmosGeoPoint":442,"geoPoint":444,"contacts":445},"Södersjukhuset","11883",{"type":122,"coordinates":443},[431,432],{"lat":432,"lon":431},[446],{"name":447,"role":107,"phone":69,"phoneExt":69,"email":448},"David Kurén, MD","david.kudren@regionstockholm.se",{"facility":450,"status":117,"city":451,"state":69,"zip":452,"country":360,"countryCode":361,"cosmosGeoPoint":453,"geoPoint":457,"contacts":458},"Norrlands universitetssjukhus","Umeå","907 37",{"type":122,"coordinates":454},[455,456],20.25972,63.82842,{"lat":456,"lon":455},[459],{"name":460,"role":107,"phone":461,"phoneExt":69,"email":462},"Hani Adamo, MD","+460704717954","hani.adamo@regionvasterbotten.se",{"facility":464,"status":117,"city":465,"state":69,"zip":69,"country":360,"countryCode":361,"cosmosGeoPoint":466,"geoPoint":470,"contacts":471},"Akademiska sjukhuset, Uppsala","Uppsala",{"type":122,"coordinates":467},[468,469],17.63889,59.85882,{"lat":469,"lon":468},[472],{"name":473,"role":107,"phone":474,"phoneExt":69,"email":475},"Mats Ahlberg, MD","+46070-2072911","mats.ahlberg@uu.se",{"type":477,"investigatorFullName":287,"investigatorTitle":478,"investigatorAffiliation":5,"oldNameTitle":69,"oldOrganization":69},"SPONSOR_INVESTIGATOR","Principal investigator",[480,481],{"name":328,"class":6},{"name":482,"class":6},"Klinbeforsk","100473719","phase-3-immediate-curative-vs-conservative-treatment-in-older-men-with-m0-high-risk-prostate-cancer-100473719",false,"NCT05448547","Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer","A Randomized, Open-label, Multicenter, Parallel Group Treatment, Phase 3, Two-arm Study to Measure the Effect on Overall Survival and Quality of Life of Immediate Curative Therapy Compared With Standard Conservative Treatment in Older Male Participants Aged ≥ 75 Years With Non-metastatic, High-risk Prostate Cancer","GrandP\u002FSPCG19","Inclusion Criteria:\n\n1. Participant must be 75 years of age or older, at the time of signing the informed consent.\n2. Participants who are healthy as determined by medical evaluation and geriatric G8\u002F miniCOGTM evaluation (G8: Fit, score \\>14, or reversibly frail; miniCOGTM: score \\>2)\n\n   And who have PCa (diagnosed ≤6 months) with one or both of the following features:\n   * Gleason grade 8-10 (ISUP group 4 and 5) other than microscopic, low-volume disease (tumor must be either palpable or visible on MRI, i.e., PIRADS 4 or 5)\n   * Locally advanced PCa (T3 or T4) (unequivocal findings of clinical\u002F radiological T3 or clinical\u002F radiological T4 on DRE or MRI; broad capsular contact of tumor on MRI is treated as localized disease, T2, in the context of this study)\n   * Able to read, understand and fill in HRQoL questionnaires (PROMS)\n3. Male\n4. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\nExclusion Criteria:\n\nMedical Conditions\n\n1. Dementia (unable to consent) Prior\u002FConcomitant Therapy\n2. Prior radiation to the pelvis\n3. Hormone therapy \\>3 months prior to randomization Diagnostic assessments\n4. Lymph node metastasis (N0) on MRI, CT or PSMA-PET CT (equivocal N-findings =N0; borderline cases will be discussed and called by a study tumor board).\n5. Distant metastasis (M0) on MRI, CT, bone scan or PSMA-PET CT (equivocal bone scan findings need to be confirmed with MRI or CT; borderline cases will be discussed by a study tumor board).\n\n   Other Exclusions\n6. Disabled or severe comorbidity (identified by G8 screening)\n7. Unable to read, understand or fill out HRQoL questionnaires (PROMS)",true,"MALE","75 Years",{"count":495,"type":496},980,"ESTIMATED","INTERVENTIONAL",[499],"PHASE3","It is currently unclear if immediate curative treatment (radiotherapy or surgery) of high-risk prostate cancer without metastasis in older men (\\>=75 years) generates the same survival benefits as in younger patients or if the harms\u002F side-effects of immediate curative treatment outweigh the benefits. In this study the investigators randomize older patients with high-risk, non-metastatic high-risk prostate cancer to either immediate curative therapy or to conservative, more problem-oriented therapy to investigate if immediate curative treatment prolongs life, improves quality of life and is cost-effective.",[502],"Prostate Cancer",[504,505,506,507],"prostate cancer","older patients","immediate curative treatment","conservative treatment","2026-09-07",{"date":510,"type":511},"2026-09-10","ACTUAL",{"date":513,"type":511},"2022-11-04",{"date":515,"type":496},"2036-12-31",{"name":287,"class":6},26]